[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100567249":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":25,"centralContacts":29,"locations":41,"responsibleParty":63,"collaborators":65,"id":72,"slug":73,"hasResults":74,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":74,"sex":80,"minAge":81,"maxAge":25,"enrollmentInfo":82,"targetDuration":25,"studyType":85,"phases":86,"briefSummary":88,"conditions":89,"keywords":94,"overallStatus":98,"whyStopped":25,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":108},{"fullName":5,"class":6},"Department of Medical Services Ministry of Public Health of Thailand","OTHER_GOV",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Early receiving G-CSF group","ACTIVE_COMPARATOR","Early receiving G-CSF group Patients in early receiving G-CSF group accept within 72 hours post chemotherapy",[13],"Drug: Early receiving G-CSF group",{"label":15,"type":16,"description":17,"interventionNames":18},"Late receiving G-CSF group","PLACEBO_COMPARATOR","Last receiving G-CSF group Patients in early receiving G-CSF group accept after 72 hours post chemotherapy",[19],"Drug: Late receiving G-CSF group",[21,26],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Early receiving G-CSF group will be given within 72 hours post chemotherapy",[9],null,{"type":22,"name":15,"description":27,"armGroupLabels":28,"otherNames":25},"Late receiving G-CSF group will be given after 72 hours post chemotherapy",[15],[30,36],{"name":31,"role":32,"phone":33,"phoneExt":34,"email":35},"Praviwan Thungthong PT Rajavithi Hospital, M.D.","CONTACT","+662-206-2900","10526","pthungthong@gmail.com",{"name":37,"role":32,"phone":38,"phoneExt":39,"email":40},"Supat Chamnanchanunt SC Department of Clinical Tropical Medicine, Mahidol University, M.D.","+662-354-9100","2060","supat.cha@mahidol.ac.th",[42,54,59],{"facility":43,"status":25,"city":44,"state":44,"zip":45,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":25},"Department of Clinical Tropical Medicine, Faculty of Tropical Medicine, Mahidol University","Bangkok","10400","Thailand","TH",{"type":49,"coordinates":50},"Point",[51,52],100.50144,13.75398,{"lat":52,"lon":51},{"facility":55,"status":25,"city":44,"state":44,"zip":45,"country":46,"countryCode":47,"cosmosGeoPoint":56,"geoPoint":58,"contacts":25},"Rajavithi Hospital",{"type":49,"coordinates":57},[51,52],{"lat":52,"lon":51},{"facility":60,"status":25,"city":61,"state":61,"zip":62,"country":46,"countryCode":47,"cosmosGeoPoint":25,"geoPoint":25,"contacts":25},"Internal Medicine Unit, Pranongklao Hospital","Nontaburi","11000",{"type":64,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR",[66,69],{"name":67,"class":68},"Mahidol University","OTHER",{"name":70,"class":71},"Internal Medicine Unit, Pranangklao Hospital","UNKNOWN","100567249","phase-4-outcomes-of-early-and-late-administration-g-csf-for-primary-prophylaxis-in-non-hodgkins-lymphoma-patients-100567249",false,"NCT06665737","Outcomes of Early and Late Administration G-CSF for Primary Prophylaxis in Non-Hodgkin's Lymphoma Patients","A Comparison Outcomes of Early and Late Administration G-CSF for Primary Prophylaxis in Non-Hodgkin's Lymphoma Patients Who Receive Chemotherapy, Multicenter Study","G-CSF in NHL","Inclusion Criteria:\n\n* Aged 18 years or old\n* Confirmed lymphoma undergoing standard chemotherapy\n* Signed an approval informed consent\n* Has a good understanding of Thai\n* Available for follow-up after chemotherapy\n\nExclusion Criteria:\n\n* Pregnancy or lactation\n* Serious concomitant diseases and discontinuous treatment such as cardiovascular, liver, or kidney diseases\n* Contraindication to chemotherapy or G-CSF administration\n* Antibiotic use within 1 week prior to enrollment","ALL","18 Years",{"count":83,"type":84},126,"ESTIMATED","INTERVENTIONAL",[87],"PHASE4","The goal of this clinical trial is to\n\nPrimary Objectives:\n\n1. To compare the incidence of febrile neutropenia in patients with non-Hodgkin's lymphoma who received early or late granulocyte colony-stimulating factor (G-CSF) during standard chemotherapy in a multicenter study\n2. To determine the incidence of leukopenia and neutropenia in patients with non-Hodgkin's lymphoma who received early or late G-CSF during standard chemotherapy in a multicenter study\n\nSecondary Objectives:\n\n1. To determine changes in white blood cell, hemoglobin, and platelet levels in patients with non-Hodgkin's lymphoma who received early or late G-CSF during standard chemotherapy.\n2. To determine the quality of life of patients with non-Hodgkin's lymphoma who undergoing standard chemotherapy and with neutropenia Researchers will compare the outcome between patients received either early G-CSF (within 72 hours) or late G-CSF (after 72 hours).\n\nAll patients will be followed up to monitor for febrile neutropenia events, other hematological parameters and quality of life.",[90,91,92,93],"Non-Hodgkin's Lymphoma (NHL)","Granulocyte Colony Stimulating Factor","Febrile Neutropenia (FN)","Myelosuppression Adult",[95,96,91,97],"Non-Hodgkin's lymphoma","Febrile neutropenia","Myelosuppression","NOT_YET_RECRUITING","2025-01-24",{"date":101,"type":102},"2025-01-28","ACTUAL",{"date":104,"type":84},"2025-02-01",{"date":106,"type":84},"2026-12-31",{"name":5,"class":6},3]